Table 3.
Tumor progression in progressive and de novo MIBC patients.
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | |
| (A) Progressive MIBC | ||||
| FLNC | 2.73 (1.06–7.05) | 0.038 | – | 0.503 |
| FGFR1 | 2.93 (1.14–7.56) | 0.026 | – | 0.150 |
| RBPMS2 | 3.97 (1.23–12.75) | 0.021 | 8.73 (1.72–44.23) | 0.009* |
| Pathological stage | 1.50 (1.07–2.09) | 0.017 | – | 0.332 |
| (B) De novo MIBC | ||||
| ITGA5 | 2.61 (1.17–5.83) | 0.019 | – | 0.110 |
| DSC3 | 0.21 (0.08–0.55) | 0.001 | 0.20 (0.05–0.75) | 0.017* |
| MSI1 | 2.97 (1.08–8.15) | 0.034 | – | 0.490 |
| PGM5 | 2.51 (1.03–6.10) | 0.042 | – | 0.056 |
| SNAI1 | 2.56 (1.02–6.42) | 0.046 | – | 0.727 |
HR Hazard ratio, CI confidence interval.
*Statistically significant values are in bold.